NCT00429104View on ClinicalTrials.gov

Herceptin and GM-CSF for Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

Herceptin

4 mg/kg IV Over 90 Minutes

DRUG

GM-CSF

250 mcg/m\^2 Subcutaneously

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00429104 - Herceptin and GM-CSF for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter